Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artra GroupTSE:6029 +0.51%57 EBIT per Share is 円3.47 as of Dec. 2025. GuruFocus rates TSE:6029 with a GF Score™ of 57/100 and a GF Value™ of 円140.25 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Artra Group ranks better than 99.43% on this metric.
Artra Group's EBIT per Share for the
three
months ended in Dec. 2025 was 円0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円3.47.
During the past 12 months, the average EBIT per Share Growth Rate of Artra Group was 2366.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 262.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Artra Group's EBIT per Share or its related term are showing as below:
TSE:6029'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -56 Med: -8.05 Max: 262
Current: 262
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Artra Group was 262.00% per year. The lowest was -56.00% per year. And the median was -8.05% per year.
TSE:6029's 3-Year EBIT Growth Rate is ranked better than 99.43% of 523
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs TSE:6029: 262.00
Artra Group's EBIT for the
three
months ended in Dec. 2025 was 円0 Mil.
Artra Group (TSE:6029) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Artra Group EBIT per Share Related Terms
Artra Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Artra Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artra Group (TSE:6029) has a EBIT per Share of 円3.47 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Artra Group and its competitors. According to the industry distribution chart, Artra Group ranks #3 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 0.59999999999999%.
Is Artra Group's EBIT per Share too high?
Artra Group's current EBIT per Share is 円3.47. Based on the distribution chart, Artra Group ranks #3 out of 523 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Artra Group has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Artra Group's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Artra Group ranks #3 out of 523 companies for EBIT per Share. This places Artra Group in the top 1% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Artra Group and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artra Group's current EBIT per Share is 円3.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artra Group stock overvalued right now?
Based on GuruFocus' analysis, Artra Group (TSE:6029) is currently considered Significantly Overvalued. The stock's GF Value™ is 円140.25, compared to a current price of 円199.00 — trading 41.9% above its estimated fair value. The current EBIT per Share is 円3.47. Artra Group's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Artra Group (TSE:6029), the current EBIT per Share is 円3.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artra Group (TSE:6029) Overvalued in 2026?
Based on GuruFocus' analysis, Artra Group stock appears to be overvalued.
The current stock price of 円199.00 is trading 41.9% above its estimated GF Value™ of 円140.25.
GuruFocus considers Artra Group to be Significantly Overvalued.
Key valuation signals for TSE:6029:
EBIT per Share: 円3.47
GF Value™: 円140.25 vs. price of 円199.00 (41.9% above fair value)
No single metric tells the full story. See the TSE:6029 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artra Group Corp is engaged in the healthcare support business, providing services that assist the operation and management of clinics and related facilities. The group has two reportable segments: Acupuncture & Orthopedic Clinic Support and Toy Sales Business. The Acupuncture and Orthopedic Clinic Support segment is involved in supporting acupuncture and orthopedic clinics through services such as bone setting chains, provision of equipment and consumables, Attra billing services, HONEY-STYLE, and nursing care support. The Toy Sales segment focuses on the sale of toys, stationery, and other related products.
57GF Score
Get the complete analysis for TSE:6029
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6029 has been successfully added to your 
